BioCentury | Apr 6, 2019
Finance

Big caps under pressure

Biogen’s fall in the wake of its decision to discontinue late-stage trials of Alzheimer’s therapy aducanumab is yet another reminder that large caps are in dire need of new pipeline products, and could serve as...
BioCentury | Oct 6, 2018
Finance

Seeking validation

The final stretch of the year offers clinical catalysts and early launch data that could validate investments in hot immuno-oncology targets and large untapped markets. Late-stage readouts from Vertex Pharmaceuticals Inc. in cystic fibrosis and...
BC Week In Review | Jul 13, 2018
Financial News

Assembly raises $144M follow-on

Assembly Biosciences Inc. (NASDAQ:ASMB) raised $144 million late on July 11 through the sale of 4 million shares at $36 in a follow-on underwritten by Jefferies, Leerink, William Blair, Mizuho Securities, Baird and National Securities...
BC Extra | Jul 12, 2018
Financial News

Assembly raises $144M follow-on

Assembly Biosciences Inc. (NASDAQ:ASMB) raised $144 million late Wednesday through the sale of 4 million shares at $36 in a follow-on underwritten by Jefferies, Leerink, William Blair, Mizuho Securities, Baird and National Securities Corp. The...
BC Week In Review | Apr 13, 2018
Clinical News

Assembly reports Phase Ib data for HBV candidate

Assembly Biosciences Inc. (NASDAQ:ASMB) reported data from the Phase Ib ABI-H0731-101b trial in treatment-naïve patients with chronic HBV infection showing that ABI-H0731 was generally well tolerated with no serious adverse events or dose-limiting toxicities (DLTs)...
BioCentury | Jan 6, 2018
Finance

Burgeoning bellwethers

  The miserable performance of large cap biotechs last quarter is likely to be a boon for small- and mid-cap players this year, in more ways than one. Buysiders spent most of 2017 focusing to...
BC Week In Review | Nov 10, 2017
Financial News

Assembly raises $60.2M in folllow-on

On Nov. 2, Assembly Biosciences Inc. (NASDAQ:ASMB) raised $60.2 million through the sale of 2.2 million shares at $27.25 in a follow-on underwritten by Jefferies and William Blair. The price is a 5% discount to...
BC Extra | Nov 2, 2017
Financial News

Intellia, Assembly price follow-ons

Intellia Therapeutics Inc. (NASDAQ:NTLA) and Assembly Biosciences Inc. (NASDAQ:ASMB) each priced follow-ons, raising more than $210 million. Intellia raised $150 million late Wednesday through the sale of 6.3 million shares at $24 in a follow-on...
BioCentury | Aug 12, 2017
Product Development

HBV test kitchen

Early results for HBV monotherapies are pointing the way toward combinations that could deliver a functional cure. What remains unknown is how many components, and which ones, will prove necessary to eliminate remnants of the...
BioCentury | Jul 8, 2017
Finance

A clinical quarter

Buysiders will find themselves digesting at least 23 Phase III data readouts in the next quarter, two of which could provide clarity on increasingly competitive markets in lung cancer and hemophilia. The third quarter is...
Items per page:
1 - 10 of 11